Peregrine Pharmaceuticals Inc. has received $-0.03 as the consensus Earnings Estimate for the Quarter ending on Jan 2017 ,According to the estimate provided by 2 Financial Advisor in the Stock Trading Firms. Among 2 Analysts, Bottom line EPS Estimate for the current quarter is $-0.03 while the top line estimate is $-0.03 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at 62.5%.
Peregrine Pharmaceuticals Inc. reported better than expected with a surprise EPS of 33.33% or $0.01 during its most recent quarterly earnings. The Actual EPS was $-0.02 compared to the Estimated EPS of $-0.03. Tustin based Peregrine Pharmaceuticals Inc. Last reported the Quarter results on Oct 31, 2016 and the Next earnings date is scheduled to be released on Mar 08, 2017.
In the last quarter, Peregrine Pharmaceuticals Inc. reported Annual Earnings of $-0.02. Based on the filings, last years Annual Earnings was, $-0.28. In the last Quarter, PPHM reported a surprise Earnings per Share of 33.33% . The consensus estimate for current quarter is $-0.03 and for the current fiscal year, the estimate is $-0.12. For the Next fiscal year, the estimate is $-0.08 based on the consensus.
Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) : On Tuesday heightened volatility was witnessed in Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) which led to swings in the share price. The stock opened for trading at $0.3 and hit $0.3089 on the upside , eventually ending the session at $0.2997, with a gain of 4.46% or 0.0128 points. The heightened volatility saw the trading volume jump to 1,719,494 shares. The 52-week high of the share price is $1.12 and the company has a market cap of $77 million. The 52-week low of the share price is at $0.282 .
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidate bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers.